SPOTLIGHT: Renovis licensee expands Phase III trial


AstraZeneca, Renovis' exclusive licensee for Cerovive, a drug for stroke victims, has boosted planned enrollment in its Phase III trial to 3,200 patients from 1,700, resulting in a delay of up to one year in regulatory filing. AstraZeneca is adding at least 10 countries to the trial in hopes of increasing the rate of enrollment and cutting the time lag. Release

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.